1-3 of 3
David P Tuck, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preclinical Activity of IRAK4 Kinase Inhibitor CA-4948 Alone or in Combination with Targeted Therapies and Preliminary Phase 1 Clinical Results in Non-Hodgkin Lymphoma

Robert N Booher, PhD, Grzegorz S. Nowakowski, MD, Krish Patel, MD, Matthew A. Lunning, DO, Maria Elena S. Samson, B.S., Ruzanna Atoyan, MD, Anna W Ma, MS, Guang-Xin Xu, BS, Steven Dellarocca, B.S., Holly Modafferi, BS, Mylissa Borek, B.S., Zhidong Zhang, PhD, Jefferson Parker, PhD, Duncan Whitney, PhD, Hongwei Wang, MD, David P Tuck, MD, Anas Younes, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4168.
https://doi.org/10.1182/blood-2018-99-117383
Published: 2018
Journal Articles

A Pooled Analysis of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients Treated with the Dual PI3K and HDAC Inhibitor Fimepinostat (CUDC-907), Including Patients with MYC-Altered Disease

Daniel J. Landsburg, MD, Radhakrishnan Ramchandren, MD, Petronella J Lugtenburg, MD PhD, Kevin R. Kelly, MD PhD, Anas Younes, MD, Robert Gharavi, PharmD, David P. Tuck, MD, Stefan Klaus Barta, MD MRCP, MS
Journal: Blood
Blood (2018) 132 (Supplement 1): 4184.
https://doi.org/10.1182/blood-2018-99-112527
Published: 2018
Journal Articles

The Combination of Venetoclax and CUDC-907 Exhibits Synergistic Activity in Venetoclax-Refractory DLBCL

Kaiming Sun, PhD, Ruzanna Atoyan, MD, Mylissa A Borek, MS, Steven Dellarocca, MS, Garrett Rhyasen, PhD, Ali Fattaey, PhD, David P Tuck, MD
Journal: Blood
Blood (2016) 128 (22): 4184.
https://doi.org/10.1182/blood.V128.22.4184.4184
Published: 2016